Skip to main content
SpringerLink
Log in

Presenting an Immunogenicity Risk Assessment to Regulatory Agencies

  • Chapter
Immunogenicity of Biopharmaceuticals

Part of the book series: Biotechnology: Pharmaceutical Aspects ((PHARMASP,volume VIII))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Baert, F., Noman, M., Vermeire, S., Van Assche, G., D’Haens, G., Carbonez, A., and Rutgeerts, P. 2003. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N. Engl. J. Med. 348:601–608.

    Article  PubMed  CAS  Google Scholar 

  • Benjamin, R., Cobbold, S., Clark, M. and Waldmann, H. 1986. Tolerance to rat monoclonal antibodies: implications for serotherapy. J. Exp. Med. 163:1539–1552.

    Article  PubMed  CAS  Google Scholar 

  • Bennett, C.L., Luminari, S., Nissenson, A.R., Tallman, M.S., Klinge, S.A., McWilliams, N., McKoy, J.M., Kim, B., Lyons, E.A., Trifilio, S.M., Raisch, D.W., Evens, A.M., Kuzel, T.M., Schumock, G.T., Belknap, S.M., Locatelli, F., Rossert, J., and Casadevall, N. 2004. Pure Red-cell Aplasia and epoetin therapy. N. Engl. J. Med. 351:1403–1408.

    Article  PubMed  CAS  Google Scholar 

  • Cheifetz, A., Smedle,y M., Martin, S., Reiter, M., Leone, G., Mayer, L., and Plevy, S. 2003. The incidence and management of infusion reactions to infliximab: a large center experience. Am. J. Gastroenterol. 98:1315–1324.

    Article  PubMed  CAS  Google Scholar 

  • Cheifetz, A. and Mayer, L. 2005. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mnt. Sinai J. Med. 72:250–256.

    Google Scholar 

  • Chirino, A.J., Ary, M.L., and Marshall, S.A. 2004. Minimizing the immunogenicity of protein therapeutics. Drug Discov. Today 9:82–90.

    Article  PubMed  CAS  Google Scholar 

  • EMEA. 2006a. The European Agency for the Evaluation of Medicinal Products (EMEA). Guideline on Similar Biological Medicinal Products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, EMEA/CHMP/BMWP/42832/2005 (http://www.emea.europa.eu/pdfs/human/biosimilar/4283205en.pdf)

    Google Scholar 

  • EMEA. 2006b. The European Agency for the Evaluation of Medicinal Products (EMEA). Guideline on Similar Medicinal Products containing recombinant erythropoietins, EMEA/CHMP/BMWP/94526/2005 (http://www.emea.eu.int/pdfs/human/biosimilar/9452605en.pdf).

    Google Scholar 

  • EMEA. 2007. The European Agency for the Evaluation of Medicinal Products (EMEA). Draft Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins, EMEA/CHMP/BMWP/14327/2006 (http://www.emea.europa.eu/pdfs/human/biosimilar/1432706en.pdf).

    Google Scholar 

  • FDA. 1997. US Department of Health and Human Services Food and Drug administration. Points to consider in the manufacture and testing of monoclonal antibody products for human use (http://www.fda.gov/Cber/gdlns/ptc_mab.pdf).

    Google Scholar 

  • FDA. 2002. US Department of Health and Human Services Food and Drug administration. Draft Guidance for Industry on Drugs, biologics, and medical devices derived from bioengineered plants for use in human and animals (http://www.fda.gov/cber/gdlns/bioplant.pdf).

    Google Scholar 

  • Ganson, N.J., Kelly, S.J., Scarlett, E., Sundy, J.S., and Hershfield, M.S. 2006. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase i trial of subcutaneous PEGylated urate oxidase. Arthr. Res. & Ther. 8:R12 (http://www.arthritis-research.com/content/8/1/R12)

    Article  Google Scholar 

  • Gao, G., Lebherz, C., Weiner, D.J., Grant, R., Calcedo, R., McCullough, B., Bagg, A., Zheng, Y., and Wilson, J.M. 2004. Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 103:3300–3302.

    Article  PubMed  CAS  Google Scholar 

  • Gomord, V., Chamberlain, P., Jefferis, R., and Faye, L. 2005. Biopharmaceutical production in plants: problems, solutions and opportunities. Trends Biotechnol. 23:559–565.

    Article  PubMed  CAS  Google Scholar 

  • Gupta, S., Indelicato, S.R., Jethwa, V., Kawabata, T., Kelley, M., Mire-Sluis, A.R., Richards, S.M., Rup, B., Shores, E., Swanson, S.J., and Wakshull, E. 2007. Recommendations for the design, optimization, and qualification of cell-based assays used for detection of neutralizing antibody responses elicited to biological therapeutics. J. Immunol. Method. 321:1–18

    Article  CAS  Google Scholar 

  • Hermeling, S., Crommelin, D.J., Schellekens, H., and Jiskoot, W. 2004. Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 21:897–903.

    Article  PubMed  CAS  Google Scholar 

  • Hermeling, S., Jiskoot, W., Crommelin, D., Bornaes, C., and Schellekens, H. 2005. Development of a transgenic mouse model immune tolerant for human interferon beta. Pharm. Res. 22:847–851.

    Article  PubMed  CAS  Google Scholar 

  • ICH. 1995. International conference on harmonisation (ICH) of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline S6 on Preclinical safety evaluation of biotechnology-derived pharmaceuticals, CPMP/ICH/302/95 (http://www.emea.europa.eu/pdfs/human/ich/030295en.pdf).

    Google Scholar 

  • ICH. 2005. International conference on harmonisation (ICH) of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline Q5E on Comparability of Biotechnological/Biological products subject to changes in their manufacturing process, CPMP/ICH/5721/03 (http://www.emea.europa.eu/pdfs/human/ich/572103en.pdf).

    Google Scholar 

  • Jaber, A. and Baker, M. 2007. Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays. J. Pharm. Biomed. Anal. 43:1256–1261.

    Article  PubMed  CAS  Google Scholar 

  • Koren, E., Zuckerman, L.A., and Mire-Sluis, A.R. 2002. Immune responses to therapeutic proteins in humans – clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3:349–360.

    Article  CAS  Google Scholar 

  • Kyewski, B. and Derbinski, J. 2004. Self-representation in the thymus: an extended view. Nat. Rev. Immunol. 4:688–698.

    Article  PubMed  CAS  Google Scholar 

  • Mire-Sluis, A.R., Barrett, Y.C., Devanarayan, V., Koren, E., Liu, H., Maia, M., Parish, T., Scott, G., Shankar, G., Shores, E., Swanson, S.J., Taniguchi, G., Wierda, D., and Zuckerman, L.A. 2004. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Method. 289:1–16.

    Article  CAS  Google Scholar 

  • Ottesen, J.L., Nilsson, P., Jami, J., Weilguny, D., Dühkkop, M., Bucchini, D., Havelund, S., and Fogh, J.M. 1994. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 37:1178–1185.

    Article  PubMed  CAS  Google Scholar 

  • Patten, P.A. and Schellekens, H. 2003. The immunogenicity of biopharmaceuticals. In ‘Immunogenicity of Therapeutic Biological Products’, ed. Brown, F. and Mire-Sluis, A.R., pp. 81–97. Dev. Biol. Basel, Karger, 112.

    Google Scholar 

  • Pendley, C., Schantz, A., and Wagner, C. 2003. Immunogenicity of therapeutic monoclonal antibodies. Curr. Opin. Mol. Ther. 5:172–179.

    PubMed  CAS  Google Scholar 

  • Randolph, J.F., Stokol, T., Scarlett, J.M., and MacLeod, J.N. 1999. Comparison of biological activity and safety of recombinant canine erythropoietin with that of recombinant human erythropoietin in clinically normal dogs. Am. J. Vet. Res. 60:636–642.

    PubMed  CAS  Google Scholar 

  • Roggen, E.L. 2006. Recent developments with B-cell epitope identification for predictive studies. J. Immunot. 3:137–149.

    Article  CAS  Google Scholar 

  • Rosenberg, A.S. 2003. Immunogenicity of Biological Therapeutics: a hierarchy of concerns. In ‘Immunogenicity of Therapeutic Biological Products’, ed. Brown, F. and Mire-Sluis, A.R., pp. 15–21. Dev. Biol. Basel, Karger, 112.

    Google Scholar 

  • Rosenberg, A.S. and Worobec, A. 2004a. A risk-based approach to immunogenicity of therapeutic protein products, Part 1: considering consequences of the immune response to a protein. BioPharm International, November 2004, 22–26 (www.biopharminternational.com/biopharm/article/articleDetail.jsp?id=134110underline.

    Google Scholar 

  • Rosenberg, A.S. and Worobec, A. 2004b. A risk-based approach to immunogenicity of therapeutic protein products, Part 2: considering host-specific and product-specific factors impacting immunogenicity, BioPharm International, December 2004, 34–42 (www.biopharminternational.com/biopharm/article/articleDetail.jsp?id=140695).

    Google Scholar 

  • Rosenberg, A.S. and Worobec, A. 2005. A risk-based approach to immunogenicity of therapeutic protein products, Part 3: effects of manufacturing changes in immunogenicity and the utility of animal immunogenicity studies. BioPharm International, January 2005, 32–36 (www.biopharminternational.com/biopharm/article/articleDetail.jsp?id=146216).

    Google Scholar 

  • Rosenberg, A.S. 2006. Effects of protein aggregates: an immunologic perspective. AAPS J. 8: Article 59, E501–E507 (http://www.aapsj.org/articles/aapsj080359/aapsj080359.pdf)

    Google Scholar 

  • Routledge, E., Falconer, M., Pope, H., Lloyd, I. and Waldmann, H. 1995. The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody. Transplantation 60:847–853.

    Google Scholar 

  • Schellekens, H. 2002a. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. Drug Discov. 1:457–462.

    Article  CAS  Google Scholar 

  • Schellekens, H. 2002b. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. 24:1720–1740.

    Article  CAS  Google Scholar 

  • Shankar, G., Shores, E., Wagner, C. and Mire-Sluis, A. 2006. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol. 24:274–280.

    Article  PubMed  CAS  Google Scholar 

  • Soos, J.M., Polsky, R.M., Keegan, S.P., Bugelski, P., and Herzyk D.J. 2003. Identification of natural antibodies to interleukin-18 in the sera of normal humans and three nonhuman primate species. Clin. Immunol. 109:188–196.

    Article  PubMed  CAS  Google Scholar 

  • Strand, V., Kimberly, R., and Isaacs, J.D. 2007. Biologic therapies in rheumatology: lessons learned, future directions. Nat. Rev. Drug Discov. 6:75–92.

    Article  PubMed  CAS  Google Scholar 

  • Tacey, R., Greway, A., Smiell, J., Power, D., Kromminga, A., Daha, M., Casadevall, N., and Kelley, M. 2003. The detection of anti-erythropoietin antibodies in human serum and plasma, Part I: validation of the protocol for a radioimmunoprecipitation assay. J. Immunol. Method. 283:317–329.

    Article  CAS  Google Scholar 

  • Tangri, S., Mothé, B.R., Eisenbraun, J., Sidney, J., Southwood, S., Briggs, K., Zinckgraf, J., Bilsel, P., Newman, M., Chesnut, R., Licalsi, C., and Sette, A. 2005. Rationally engineered therapeutic proteins with reduced immunogenicity. J. Immunol. 174:3187–3196.

    PubMed  CAS  Google Scholar 

  • Thorpe, R. and Swanson, S.J. 2005. Current methods for detecting antibodies against erythropoietin and other recombinant proteins. Clin. Diag. Lab. Immunol. 12:28–39

    Article  CAS  Google Scholar 

  • Van der Meide, P.H. and Schellekens, H. 1997. Anti-cytokine autoantibodies: epiphenomenon or critical modulators of cytokine action. Biotherapy 10:39–48.

    Article  PubMed  Google Scholar 

  • Van Walle, I., Gansemans, Y, Parren, P., Stas, P., and Lasters, I. 2007. Immunogenicity screening in protein drug development. Expert Opin. Biol. Ther. 7:405–418.

    Google Scholar 

  • Wagner, C.L., Schantz, A., Barnathan, E., Olson, A., Mascelli, M.A., Ford, J., Damaraju, L., Scaible, T., Maini, R.N., and Tcheng, J.E. 2003. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro® and Remicade®. In ‘Immunogenicity of Therapeutic Biological Products’, ed. Brown, F. and Mire-Sluis, A.R., pp. 37–53. Dev. Biol. Basel, Karger, 112.

    Google Scholar 

Download references

Authors
  1. Paul Chamberlain
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Copenhagen, Copenhagen, Denmark

    Marco van de Weert

  2. University of Copenhagen, Copenhagen, Denmark

    Eva Horn Møller

Rights and permissions

Reprints and permissions

Copyright information

© 2008 American Association of Pharmaceutical Scientists

About this chapter

Cite this chapter

Chamberlain, P. (2008). Presenting an Immunogenicity Risk Assessment to Regulatory Agencies. In: Weert, M.v., Møller, E.H. (eds) Immunogenicity of Biopharmaceuticals. Biotechnology: Pharmaceutical Aspects, vol VIII. Springer, New York, NY. https://doi.org/10.1007/978-0-387-75841-1_13

Download citation

Publish with us

Policies and ethics

Societies and partnerships

Search

Navigation